AstraZeneca says no severe virus cases or deaths after taking antibody

AstraZeneca PLC late Wednesday said a clinical trial found its Evusheld antibody therapy markedly reduced the risk of developing symptomatic Covid-19.

The drugmaker added that in a six-month follow-up of the Provent phase III trial, there were no severe Covid-19 cases of deaths.